mlipi as a predictor of nivolumab outcomes in advanced nsclc
Published 5 years ago • 52 plays • Length 2:17Download video MP4
Download video MP3
Similar videos
-
3:44
immunotherapy as combination and neoadjuvant therapies in nsclc
-
1:08
the tumor-myeloid axis as a predictor of response to immunotherapy in nsclc
-
3:34
clinical outcomes of immunotherapy after radiographic progression in advanced nsclc
-
2:53
delta-radiomics predicting response and overall-survival in advanced nsclc treated with durvalumab
-
2:16
treatment resistance as a key challenge in patients with advanced nsclc
-
2:39
neoadjuvant nivolumab with or without chemotherapy in resectable nsclc
-
2:03
antibiotics impact outcomes with pembrolizumab in nsclc patients
-
29:57
nsclc disease overview and long term survival outcomes with nivolumab in mnsclc
-
44:56
advanced nsclc: refining clinical pathways in the rapidly evolving therapeutic landscape
-
2:26
nivolumab and ipilimumab in advanced merkel cell carcinoma
-
6:09
efficacy and early discontinuation predictors in nsclc patients receiving nivolumab
-
6:13
checkmate-227: testing ipilimumab/nivolumab in nsclc
-
6:03
checkmate 9la: nivolumab, ipilimumab and chemotherapy for stage iv nsclc
-
6:16
treatment-free survival results of nivolumab and salvage nivolumab ipilimumab for accrcc
-
8:01
fda activity for nivolumab, t-vec in melanoma, new lung cancer findings, mds findings, and more
-
4:22
nivolumab in non-small cell lung cancer
-
11:30
asco 2021 lung recap: surgical outcomes & checkmate 816: nivolumab in early stage nsclc
-
0:43
dr. renato g. martins on nivolumab and its role as a second-line treatment in nsclc
-
2:24
perioperative nivolumab in resectable nsclc | nejm